Qorvo layoffs, on the record
Every job cut, severance charge and restructuring Qorvo reported in its annual reports, 2024 to 2026, quoted from the filings. Headcount went from approximately 8,700 to approximately 5,200.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2024 | approximately 8,700 | March 30, 2024 |
| 10-K for 2025 | approximately 6,200 | March 29, 2025 |
| 10-K for 2026 | approximately 5,200 | March 28, 2026 |
Job cuts, severance and restructuring
Our summaryQorvo entered into an agreement to divest its assembly and test operations in Beijing and Dezhou, China to Luxshare, completed on May 2, 2024 (2024 Restructuring Initiative).
Word for word“During fiscal 2025, the Company expects to incur additional charges associated with the 2024 Restructuring Initiative of approximately $ 5.0 million to $ 10.0 million, primarily related to employee termination benefits and legal and consulting fees.” 10-K for 2024
Our summaryQorvo recorded one-time employee termination benefits under the 2024 Restructuring Initiative.
Word for word“The following table summarizes fiscal 2024 charges resulting from the 2024 Restructuring Initiatives (in thousands): Cost of Goods Sold Other Operating Expense Total Contract termination and other costs $ — $ 7,213 $ 7,213 Asset impairment costs (1) 1,213 35,733 36,946 One-time employee termination benefits — 8,887 8,887 Total $ 1,213 $ 51,833 $ 53,046 (1) Refer to Note 4 for additional information.” 10-K for 2024
Our summaryQorvo completed its 2023 Restructuring Initiatives, which included seeking strategic alternatives for its non-core biotechnology business, and recorded one-time employee termination benefits.
Word for word“As of March 30, 2024, the Company has incurred cumulative charges of $ 163.9 million related to the 2023 Restructuring Initiatives.” 10-K for 2024
Our summaryQorvo idled a BAW manufacturing facility in Texas in fiscal 2021 to address manufacturing overcapacity and later sold it in fiscal 2024, with resulting impairment and restructuring-related charges.
Word for word“For example, to address manufacturing overcapacity, we idled a BAW manufacturing facility in Texas in fiscal 2021, and subsequently sold the facility in fiscal 2024.” 10-K for 2024
Our summaryQorvo initiated 2025 Restructuring Initiatives to reduce operating expenses, streamline its manufacturing footprint and focus on long-term profitability, including one-time employee termination benefits.
Word for word“The following table summarizes the charges resulting from the 2025 Restructuring Initiatives (in thousands): Fiscal 2025 Cost of Goods Sold Goodwill and Intangible Asset Impairment Other Operating Expense Total Contract termination and other costs $ 11,622 $ — $ 43,443 $ 55,065 Asset impairments and gain on sale of business (1) 14,359 192,569 ( 10,914 ) 196,014 One-time employee termination benefits — — 7,788 7,788 Total $ 25,981 $ 192,569 $ 40,317 $ 258,867 (1) "Other Operating Expense" includes a gain on sale of the SiC power device business.” 10-K for 2025
Our summaryQorvo expects to incur additional charges under the 2025 Restructuring Initiatives, primarily for employee termination benefits and legal and consulting fees.
Word for word“During fiscal 2026, the Company expects to incur additional charges associated with the 2025 Restructuring Initiatives of approximately $ 15.0 million to $ 20.0 million, primarily related to employee termination benefits and legal and consulting fees.” 10-K for 2025
Our summaryQorvo completed the divestiture of its assembly and test operations in Beijing and Dezhou, China to Luxshare under the 2024 Restructuring Initiative, with one-time employee termination benefits recorded.
Word for word“The sale of these operations (the "2024 Restructuring Initiative") was completed in the first quarter of fiscal 2025 (refer to Note 4 for additional information).” 10-K for 2025
Our summaryQorvo recorded charges under the 2023 Restructuring Initiatives, which included employee termination benefits and the sale of its biotechnology business.
Word for word“During fiscal 2023, the Company initiated actions to improve efficiencies in its operations and further align the organization with its strategic objectives, which primarily included seeking strategic alternatives related to its biotechnology business (the "2023 Restructuring Initiatives" and, together with the 2025 Restructuring Initiatives and the 2024 Restructuring Initiative, the "Restructuring Initiatives").” 10-K for 2025
Our summaryStarted the 2026 restructuring: closing the North Carolina fab, moving SAW filter production to Texas, and consolidating the CSG organization to cut costs.
Word for word“In the second quarter of fiscal 2026, the Company initiated further actions to reduce operating expenses, streamline its manufacturing footprint and accelerate its focus on long-term profitability objectives (the "2026 Restructuring Initiatives").” 10-K for 2026
Our summaryExpects more charges from the 2026 restructuring, mostly for employee termination benefits.
Word for word“The Company expects to incur additional charges associated with the 2026 Restructuring Initiatives of approximately $ 10.0 million to $ 20.0 million, primarily related to employee termination benefits.” 10-K for 2026
Our summaryCut its workforce tied to the mass-market Android business, sold its SiC power device business, cancelled some core systems projects, and sought alternatives for its MEMS sensing business, as part of the 2025 restructuring.
Word for word“As part of these actions, the Company reduced its workforce related to its mass-market Android business, sold its SiC power device business, cancelled certain multiyear projects to update the Company's core business systems, and began to seek strategic alternatives related to its MEMS-based sensing solutions business.” 10-K for 2026
Our summaryReported cumulative expenses to date for the 2025 restructuring, including employee termination benefits.
Word for word“As of March 28, 2026, the Company has recorded cumulative expenses of approximately $ 71.2 million for contract termination and other costs, $ 178.8 million for asset impairment costs and gain on sales of businesses, and $ 13.2 million for one-time employee termination benefits as a result of the 2025 Restructuring Initiatives.” 10-K for 2026
Our summaryRan a restructuring to sell its assembly and test operations in China, with charges in fiscal 2025 and 2024.
Word for word“During fiscal years 2025 and 2024, the Company incurred $ 18.3 million and $ 53.0 million, respectively, in restructuring-related charges in connection with an initiative that began in fiscal 2024 to divest its assembly and test operations in China (the "2024 Restructuring Initiative").” 10-K for 2026
| Fiscal year ended | Restructuring charges | Cash paid for restructuring |
|---|---|---|
| 2017-04-01 | $2.1 million | — |
| 2018-03-31 | $67.7 million | — |
| 2019-03-30 | $50.7 million | $13.5 million |
| 2020-03-28 | $47.9 million | $18.8 million |
| 2021-04-03 | $2.7 million | $3.6 million |
| 2022-04-02 | $2.1 million | — |
| 2023-04-01 | $25.7 million | $20.4 million |
| 2024-03-30 | $44.4 million | $26.1 million |
| 2026-03-28 | $7.4 million | — |
Qorvo has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Qorvo’s annual reports (10-K for 2026, 10-K for 2025, 10-K for 2024) and the financial data it files with the SEC, as of 2026-05-08. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.